Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 17/20 | 0.65 |
| ▸ | HTR7 | P34969 | 15/20 | 0.65 |
| ▸ | DRD2 | P14416 | 1/20 | 0.60 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.60 |
| ▸ | HTR2A | P28223 | 1/20 | 0.60 |
| ▸ | HTR2C | P28335 | 1/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.60 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.60 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5127590 | 0.83 | HTR2B (0.58) | HTR2BHTR7DRD2ADRA1DHTR2A | |
| SCHEMBL4921111 | 0.81 | HTR2B (0.73) | HTR2BHTR7DRD2ADRA1DHTR2A | |
| SCHEMBL4919036 | 0.79 | SRD5A2 (0.54) | PDK2 | |
| SCHEMBL4924900 | 0.79 | HTR2B (1.00) | HTR2BHTR7DRD2ADRA1DHTR2A | |
| Hydrochloric Acid SCHEMBL4918890 | 0.78 | HTR2B (0.56) | HTR2BHTR7DRD2ADRA1DHTR2A | |
| SCHEMBL4916196 | 0.77 | HTR2B (0.55) | HTR2BHTR7DRD2ADRA1DHTR2A | |
| SCHEMBL4914483 | 0.75 | HTR2B (0.52) | HTR2BHTR7DRD2ADRA1DHTR2A | |
| SCHEMBL4922102 | 0.74 | SRD5A2 (0.51) | PDK2 | |
| SCHEMBL14087443 | 0.72 | HTR2B (0.94) | HTR2BHTR7DRD2ADRA1DHTR2A | |
| SCHEMBL4923552 | 0.72 | HTR2B (1.00) | HTR2BHTR7DRD2ADRA1DHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200551-A1 | Flourene Derivative | ASTELLAS PHARMA INC. (JP) | 2008-08-21 | — | — | US | claimed |
| US-20080171788-A1 | Medicament For Irritable Bowel Syndrome | ASTELLAS PHARMA INC. (JP) | 2008-07-17 | — | — | US | claimed |
| EP-1852129-A1 | REMEDY FOR IRRITABLE BOWEL SYNDROME | Astellas Pharma Inc. (JP) | 2007-11-07 | — | — | EP | claimed |
| EP-1728784-A1 | FLUORENE DERIVATIVE | Astellas Pharma Inc. (JP) | 2006-12-06 | — | — | EP | claimed |
| US-20080200551-A1 | Flourene Derivative | ASTELLAS PHARMA INC. (JP) | 2008-08-21 | — | — | US | disclosed |
| EP-1728784-A1 | FLUORENE DERIVATIVE | Astellas Pharma Inc. (JP) | 2006-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200551-A1 | Flourene Derivative | HTR2B, HTR7, HTR2C | HTR2B 1/4885HTR7 2/4885DRD2 97/4885 |
| US-20080171788-A1 | Medicament For Irritable Bowel Syndrome | HTR7, HTR5A, HTR3B | HTR2B 4/4885HTR7 1/4885DRD2 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.